Basic Information
| LncRNA/CircRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | glioma tissues, cell lines (U87, U251 and HEK) |
| Expression Pattern | up-regulated |
| Function Description | Linc00152 was up-regulated in glioma tissues as well as in GSCs. Knockdown of linc00152 inhibited cell proliferation, migration and invasion, while promoted GSC apoptosis. Linc00152 regulated the malignant behavior of GSCs by binding to miR-103a-3p, which functions as a tumor suppressor.In addition, knockdown of linc00152 down-regulated forebrain embryonic zinc finger protein 1 (FEZF1),a direct target of miR-103a-3p which played an oncogenic role in GSCs.FEZF1 elevated promoter activities and up-regulated expression of the oncogenic gene cell division cycle 25A (CDC25A).CDC25A over-expression activated the PI3K/AKT pathways, which regulated the malignant behavior of GSCs.Linc00152 knockdown combined with over-expressed miR-103a-3p suppressed tumor growth and manifested high survival in nude mice. |
| Pubmed ID | 28651608 |
| Year | 2017 |
| Title | Linc00152 promotes malignant progression of glioma stem cells by regulating miR-103a-3p/FEZF1/CDC25A pathway. |
External Links
| Links for LINC00152 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |